Minerva Neurosciences’ Clinical Data Featured at The American College of Neuropsychopharmacology Annual Meeting
Oral presentation highlights specific improvements in negative symptoms and cognition observed in schizophrenic patients treated with MIN-101 in Phase IIB trial
Data also presented from Phase IIA trials with MIN-101 and MIN-117
WALTHAM, Mass., 2016-11-30 20:41 CET (GLOBE NEWSWIRE) --Minerva Neurosciences, Inc. (NASDAQ:NERV), a clinical-stage biopharmaceutical company focused on the development of therapies to treat central nervous system (CNS) disorders, today announced data presentations at the 55th Annual Meeting of the American College of Neuropsychopharmacology (ACNP), December 4-8, 2016. Conclusions from these data analyses are summarized below. The posters will be available following the completion of the last of these presentations at the ACNP meeting at http://ir.minervaneurosciences.com/events.cfm.
“The presentations of data from the Phase IIB trial with MIN-101 at ACNP demonstrate broad internal consistency across multiple endpoints, supporting the direct effect of this compound in treating negative symptoms in schizophrenia,” said Dr. Remy Luthringer, president and chief executive officer of Minerva. “Beyond the significant improvement on negative symptoms observed in the core 12-week double blind phase of this trial, which was followed by continuous improvement experienced by patients over an additional 24-week extension phase, data presented at ACNP show the potential of treatment with MIN-101 in improving general psychopathology, cognition and sleep, as well as its marked impact on younger patients.”
1. Abstract title: “Efficacy and Safety of MIN-101: A New Drug for the Treatment of Negative Symptoms in Schizophrenia” (Hot Topics oral presentation session and Poster Session I, Poster Board M218)
Data from the Phase IIB trial (top line results from which were first announced in May 2016) demonstrated a statistically significant improvement in negative symptoms as measured by both the pentagonal structure model of the Positive and Negative Symptom scale and the classic PANSS three factors negative symptoms subscale for both doses tested, 32 milligrams (mg) and 64 mg. The statistically significant superiority of MIN-101 over placebo was also observed on most secondary outcomes such as the PANSS total score, Clinical Global Impression of Improvement (CGI-I), Clinical Global Impression of Severity (CGI-S), Brief Negative Symptoms Scale (BNSS) total score, Personal and Social Performance (PSP) total score, and Calgary Depression Scale for Schizophrenia (CDSS).
The direct effect of MIN-101 on negative symptoms (rather than an indirect effect secondary to improvements in other symptoms) was underscored by the observed stability in positive symptoms, the absence of extra-pyramidal symptoms (EPS) and the persistence of this specific effect even after controlling for improvements in depressive symptoms. Researchers noted that since phenomena similar to negative symptoms are manifest in many psychiatric disorders and in brain degenerative disorders such as Azheimer’s disease and Parkinson’s disease, future trials with MIN-101 could be designed to explore its potential benefit in these patient populations.
In post-hoc analysis, improvement in negative symptoms was shown to be greatest among younger patients, especially in the cohort of patients under 33 years of age. This finding supports the potential therapeutic intervention with MIN-101 in younger patients with schizophrenia who are beginning to manifest these symptoms. It is also consistent with research showing that chronic pharmacotherapeutic intervention in schizophrenia, which includes atypical antipsychotics to treat acute positive symptoms, becomes less effective as patients age and suffer long-term consequences of the disease and side effects of current treatment options.
With respect to safety and tolerability, no weight gain or clinically significant changes from baseline in vital signs, prolactin, routine laboratory values and EPS measurements were observed. As previously announced, two patients out of 162 who received MIN-101 in the core phase of the trial were discontinued based upon discontinuation criteria related to QTcF prolongation; both of these patients received the higher dose (64 mg). In the extension phase of the trial, no additional patients were discontinued.
2. Abstract title: “Effect of MIN-101 on Cognition in Schizophrenia Patients With Predominant Negative Symptoms: A 12-Week Randomized, Double Blind, Placebo-Controlled Trial” (Poster Session II, Poster Board T167)
Results from the Phase IIB, double-blind, randomized, placebo-controlled study suggest a benefit of treatment with MIN-101 32 mg in improving cognitive function in schizophrenia patients with predominant negative symptoms. Cognitive function was evaluated using the Brief Assessment of Cognition in Schizophrenia (BACS) scale, and data analyses demonstrated statistically significant differences in the BACS scale between patients treated with MIN-101 at the 32 mg dose and those who received placebo. Cognitive dysfunction, a core feature of schizophrenia, affects up to 75 percent of patients and is viewed as a good predictor of functional outcome.
3. Abstract title: “MIN-101 Improves Sleep in Patients Suffering From Schizophrenia: A Randomized, Placebo-Controlled, Double Blind Study” (Poster Session III, Poster Board W192)
Results from a Phase IIA, double-blind, randomized, placebo-controlled study showed that treatment with MIN-101 as monotherapy was associated with significantly improved sleep induction and normalized slow wave sleep (SWS) ultradian distribution during the night, which are two key sleep parameters that are disturbed in schizophrenia. Such disturbances of sleep architecture and continuity may be associated with memory consolidation, which is impaired in schizophrenia. These effects on sleep parameters may help to improve the overall symptomatology observed in patients suffering from schizophrenia and treated with MIN-101.
4. Abstract title: “A Randomized, Double-Blind, Parallel-Group, Placebo- and Active-Controlled Study to Evaluate the Efficacy and Safety of MIN-117 in Patients With Major Depressive Disorder” (Poster Session II, Poster Board T132)
Results from a Phase IIA clinical trial demonstrated the dose-dependent superiority of MIN-117 over placebo in reducing symptoms of depression as measured by the Montgomery-Asberg Depression Rating Scale (MADRS). Twenty-four percent of patients treated with MIN-117 were observed to achieve remission as prospectively defined. In addition, MIN-117 was observed to preserve sleep continuity and architecture and therefore is not expected to have detrimental effects on rapid eye movement (REM) sleep distribution and duration. MIN-117 also demonstrated a favorable tolerability profile, and the incidence and types of side effects did not differ significantly from placebo. Treatment with MIN-117 was not associated with cognitive impairment, sexual dysfunction, suicidal ideation or weight gain.
MIN-101 is a drug candidate with equipotent affinities for sigma 2 and 5‑hydroxytryptamine-2A (5-HT2A) and lower affinity at α1-adrenergic receptors. MIN-101 has no direct dopaminergic post-synaptic blocking effects, known to be involved in some side effects like extrapyramidal symptoms, sedation, prolactin increases and weight gain.
MIN-117 is an antidepressant drug candidate with a differentiated mechanism of action targeting adrenergic alpha 1a, alpha 1b, 5-HT1A, 5-HT2A receptors, serotonin and the dopamine transporters.
About Minerva Neurosciences
Minerva Neurosciences, Inc. is a clinical-stage biopharmaceutical company focused on the development and commercialization of a portfolio of products to treat CNS diseases. Minerva’s proprietary compounds include: MIN-101, which has completed a Phase IIb clinical trial for schizophrenia; MIN-117, which has completed a Phase IIa clinical trial development for MDD; MIN-202 (JNJ-42847922), which has completed Phase IIa and Phase Ib clinical trials for insomnia and MDD, respectively; and MIN-301, in pre-clinical development for Parkinson’s disease. Minerva’s common stock is listed on the NASDAQ Global Market under the symbol “NERV.” For more information, please visit www.minervaneurosciences.com.
Forward-Looking Safe Harbor Statement
This press release contains forward-looking statements which are subject to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995, as amended. Forward-looking statements are statements that are not historical facts, reflect management’s expectations as of the date of this press release, and involve certain risks and uncertainties. Forward-looking statements include statements herein with respect to the timing and results of future clinical milestones with MIN-101 and MIN-117; the clinical and therapeutic potential of MIN-101 and MIN-117; our ability to successfully develop and commercialize MIN-101 and MIN-117; and management’s ability to successfully achieve its goals. These forward-looking statements are based on our current expectations and may differ materially from actual results due to a variety of factors including, without limitation, whether MIN-101 and MIN-117 will advance further in the clinical trials process and whether and when, if at all, they will receive final approval from the U.S. Food and Drug Administration or equivalent foreign regulatory agencies and for which indications; whether the results of future clinical trials of MIN-101 and MIN-117, if any, will be consistent with the results of past clinical trials; whether MIN-101 and MIN-117 will be successfully marketed if approved; whether our therapeutic product discovery and development efforts with MIN-101 and MIN-117 will be successful; our ability to achieve the results contemplated by our co-development agreements; management’s ability to successfully achieve its goals; our ability to raise additional capital to fund our operations on terms acceptable to us; and general economic conditions. These and other potential risks and uncertainties that could cause actual results to differ from the results predicted are more fully detailed under the caption “Risk Factors” in our filings with the Securities and Exchange Commission, including our Quarterly Report on Form 10-Q for the quarter ended September 30, 2016, filed with the Securities and Exchange Commission on November 3, 2016. Copies of reports filed with the SEC are posted on our website at www.minervaneurosciences.com. The forward-looking statements in this press release are based on information available to us as of the date hereof, and we disclaim any obligation to update any forward-looking statements, except as required by law.
William B. Boni
VP, Investor Relations/
Minerva Neurosciences, Inc.
Om Nasdaq GlobeNewswire
One Liberty Plaza - 165 Broadway
NY 10006 New York
+1 212 401 8700http://www.nasdaqomx.com
NASDAQ (NASDAQ: NDAQ) is a leading provider of trading, exchange technology, information and public company services across six continents.
Følg saker fra Nasdaq GlobeNewswire
Registrer deg med din epostadresse under for å få de nyeste sakene fra Nasdaq GlobeNewswire på epost fortløpende. Du kan melde deg av når som helst.
Siste saker fra Nasdaq GlobeNewswire
Standard Lithium Announces Closing of $21.6 million Bought Deal Private Placement of Units16.2.2018 19:25 | Pressemelding
THIS NEWS RELEASE IS INTENDED FOR DISTRIBUTION IN CANADA ONLY AND IS NOT INTENDED FOR DISTRIBUTION TO UNITED STATES NEWSWIRE SERVICES OR DISSEMINATION IN THE UNITED STATES. VANCOUVER, British Columbia, Feb. 16, 2018 (GLOBE NEWSWIRE) -- Standard Lithium Ltd. ("Standard Lithium" or the "Company") (TSX-V:SLL) (OTCQX:STLHF) (FRA:S5L) announced today that it has closed its previously announced bought deal private placement of 10,312,821 units of the Company (the "Units"), at a price of $2.10 per Unit, for aggregate gross proceeds to the Company of $21,656,924, including the issuance and sale of the Underwriters' (as defined below) option (the "Offering"). Each Unit consists of one common share of the Company and one-half of one common share purchase warrant (each whole common share purchase warrant, a "Warrant"). Each Warrant is exercisable to acquire one common share of the Company (a "Warrant Share") until February 16, 2020 at an exercise price of $2.60 per Warrant Share, subject to adjus
Cisco Offers Cloud-Based Endpoint Security Solutions for Managed Security Service Providers16.2.2018 14:00 | Pressemelding
Cisco's comprehensive cloud-based security endpoint portfolio provides advanced malware protection, internet security, and enterprise mobility management SAN JOSE, Calif., Feb. 16, 2018 (GLOBE NEWSWIRE) -- Cisco today is helping address the challenges of Managed Security Service Providers (MSSP) and their customers by offering MSSPs comprehensive security, visibility, and control of customer endpoints without added hardware or complexity. The Cisco endpoint security portfolio includes three industry-leading solutions-Cisco AMP for Endpoints, Cisco Umbrella, and Meraki Systems Manager to offer protection against advanced malware and threats. Security teams know the endpoints in their environments are being targeted by advanced threats, but often lack the security talent, tools, and budget to address those challenges. As a result, organizations of all sizes are choosing to augment their in-house IT security with managed security services. Nearly half of SMBs and enterprises in the US1 ar
Aurora Solar Adds Heterojunction Cell Characterization to Decima Gemini Family16.2.2018 14:00 | Pressemelding
Aurora Solar Technologies Inc. / Aurora Solar Adds Heterojunction Cell Characterization to Decima Gemini Family . Processed and transmitted by Nasdaq Corporate Solutions. The issuer is solely responsible for the content of this announcement. NORTH VANCOUVER, British Columbia, Feb. 16, 2018 (GLOBE NEWSWIRE) -- Aurora Solar Technologies Inc. ("Aurora") ("Company") (TSX.V:ACU) (OTCBB:AACTF) (FSE:A82) is pleased to provide an update on the further development of its Decima Gemini(TM) infrared measurement technology for applications in the rapidly developing heterojunction (HJT) cell manufacturing market. HJT is an ultra high-efficiency solar cell design pioneered by Japan's Panasonic Corp., who is now also partnered with Tesla Inc. for solar products. According to Solar Media Ltd., HJT production capacity is expected to increase by 20 percent this year. To produce the electrical structure of a HJT cell, it is necessary to apply thin layers of amorphous silicon on both sides of a crystallin
Nasdaq Cited as a Leader in Governance, Risk, and Compliance Platforms by Independent Research Firm16.2.2018 13:35 | Pressemelding
NEW YORK, Feb. 16, 2018 (GLOBE NEWSWIRE) -- Nasdaq (Nasdaq:NDAQ) was among the select companies that Forrester invited to participate in its 2018 Forrester Wave(TM) evaluation, Governance, Risk, And Compliance (GRC) Platforms, Q1 2018. In this evaluation, Nasdaq was cited as a Leader in Governance, Risk, and Compliance Platforms and received the maximum score of 5 for the evaluation criteria "Risk & Control Management", "Audit Management", "Dashboard and Reporting" and "Integration capabilities" for its BWise solutions. "We feel the strong scores we obtained in important functional areas provide assurance to our clients that they have selected a robust and future-proof software platform," said Tom Passon, Head of Product Innovation & Global Standards, Nasdaq BWise. "We are proud of this recognition that encourages us to further execute on our strategy to provide user-friendly, pre-configured best practice solutions that combine our innovative GRC software platform with leading expertis
Apricus Biosciences Receives Complete Response Letter from FDA for Vitaros(TM)16.2.2018 13:00 | Pressemelding
Company Evaluating Deficiencies and Potential Path Forward SAN DIEGO, Feb. 16, 2018 (GLOBE NEWSWIRE) -- Apricus Biosciences, Inc. (Nasdaq:APRI), a biopharmaceutical company advancing innovative medicines in urology and rheumatology, today announced that the U.S. Food and Drug Administration ("FDA") has issued a complete response letter ("CRL") for the New Drug Application ("NDA") of Vitaros(TM) (alprostadil, DDAIP.HCl), a topical cream for the treatment of erectile dysfunction. The CRL indicates that the FDA cannot approve the NDA for Vitaros in its present form, identifying deficiencies related to Chemistry, Manufacturing and Control ("CMC") and certain safety concerns specific to the 2.5% concentration of DDAIP.HCl contained in the current formulation. "We are disappointed with the outcome of the review given the substantial amount of CMC, clinical and non-clinical data and analysis provided to the FDA in the Vitaros resubmission. We are assessing the content of the complete response
SEMAFO: Positive Mana PFS and Reserve Additions at Mana and Boungou16.2.2018 03:36 | Pressemelding
5-Year Average Target of 413,000 Ounces of Annual Production, AISC $696 MONTREAL, Quebec, Feb. 15, 2018 (GLOBE NEWSWIRE) -- SEMAFO Inc. (TSX:SMF) (OMX:SMF) today announced positive pre-feasibility study (PFS) results at Mana, the addition of 188,000 ounces of reserves, primarily at Siou underground, and an increase of 203,000 ounces of reserves at Boungou. As a result, the Corporation is providing the following consolidated five-year operational targets. Table 1 - Five-Year Operational Targets ---------------------------------------------------- 2019-2023 2019 2020 2021 2022 2023 Average ---------------------------------------------------- Production(1,2,3) Mana ('000 oz) 192 213 213 213 214 209 Boungou ('000 oz) 226 226 201 186 180 204 418 439 414 399 394 413 AISC(1,2,4,5) Mana ($/oz) 906 1,079 887 823 660 871 Boungou ($/oz) 419 405 527 606 626 516 643 733 712 721 643 696 Operating Cash Flow (at $1,300/oz) Total Revenue ($M) 543 571 539 518 512 2,683 AISC ($M) 268 321 295 287 253 1,42
I vårt presserom finner du alle våre siste saker, kontaktpersoner, bilder, dokumenter og annen relevant informasjon om oss.Besøk vårt presserom